
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is poised for strong top-line growth in 2026 and beyond, driven not only by key commercial products like Repatha and Tezspire, but also by the continued strength of its rare disease segment, particularly its drug Uplizna. The company's positive 1Q 2026 performance, with sales and EPS beating estimates, is a testament to its strong product portfolio and pipeline, making it an attractive investment with an overweight rating and a PT of $427.
Bears say
Amgen is a biotechnology-based human therapeutics company that has a solid portfolio of flagship drugs, including Epogen, Aranesp, Neupogen, and Enbrel, among others. However, the company faces headwinds in the near future due to competition from generic drugs and slower-than-expected sales for certain products. These factors, along with increased concerns about regulatory and pricing risks, lead to a negative outlook for the company's financial performance.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares